<?xml version="1.0" encoding="utf-8"?>
<law>
    <structure>
        <unit label="part" identifier="1" order_by="1" level="1">Administration Of The Government</unit>
        <unit label="title" identifier="22" order_by="22" level="2">Corporations</unit>
        <unit label="chapter" identifier="176A" order_by="176A" level="3">Non Profit Hospital Service Corporations</unit>
    </structure>
    <section_number>8V</section_number>
    <catch_line>Coverage For Human Leukocyte Or Histocompatibility Locus Antigen Testing</catch_line>
    <order_by>8V</order_by>
    <text>
        Any contract between a subscriber and the corporation under an individual or group hospital service plan, except contracts providing supplemental coverage to Medicare or to other government programs, delivered, issued or renewed by agreement within or without the commonwealth shall provide, as benefits to all individual subscribers or members within the commonwealth and to all group members having a principal place of employment within the commonwealth, coverage for the cost of human leukocyte antigen testing or histocompatibility locus antigen testing that is necessary to establish bone marrow transplant donor suitability. The coverage shall cover the costs of testing for A, B or DR antigens, or any combination thereof, consistent with rules, regulations and criteria established by the department of public health pursuant to section 218 of chapter 111.
    </text>
</law>